Desai, M. Y., Owens, A., Saberi, S., Wang, A., Wolski, K., Cremer, P. C., … VALOR-HCM Investigators. (2025). Long-Term Effects of Mavacamten on Patients Based on Hypertrophic Cardiomyopathy Pathogenic Genetic Variant Status: Insights From VALOR-HCM Trial. Circ Genom Precis Med, 18(3), e005100. https://doi.org/10.1161/CIRCGEN.125.005100

Desai, Milind Y., Anjali Owens, Sara Saberi, Andrew Wang, Kathy Wolski, Paul C. Cremer, Neal K. Lakdawala, et al. “Long-Term Effects of Mavacamten on Patients Based on Hypertrophic Cardiomyopathy Pathogenic Genetic Variant Status: Insights From VALOR-HCM Trial.” Circ Genom Precis Med 18, no. 3 (June 2025): e005100. https://doi.org/10.1161/CIRCGEN.125.005100.

Desai MY, Owens A, Saberi S, Wang A, Wolski K, Cremer PC, et al. Long-Term Effects of Mavacamten on Patients Based on Hypertrophic Cardiomyopathy Pathogenic Genetic Variant Status: Insights From VALOR-HCM Trial. Circ Genom Precis Med. 2025 Jun;18(3):e005100.

Desai, Milind Y., et al. “Long-Term Effects of Mavacamten on Patients Based on Hypertrophic Cardiomyopathy Pathogenic Genetic Variant Status: Insights From VALOR-HCM Trial.” Circ Genom Precis Med, vol. 18, no. 3, June 2025, p. e005100. Pubmed, doi:10.1161/CIRCGEN.125.005100.

Desai MY, Owens A, Saberi S, Wang A, Wolski K, Cremer PC, Lakdawala NK, Tower-Rader A, Zenker M, Sherrid M, Geske JB, Fermin D, Naidu SS, Lampl K, Nissen SE, VALOR-HCM Investigators. Long-Term Effects of Mavacamten on Patients Based on Hypertrophic Cardiomyopathy Pathogenic Genetic Variant Status: Insights From VALOR-HCM Trial. Circ Genom Precis Med. 2025 Jun;18(3):e005100.